All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
Infection risk in patients with smoldering MM
Results from a matched cohort study, with data from from the Icelandic iStopMM (NCT03327597) screening study, investigating the risk of infection in patients with smoldering multiple myeloma (SMM) compared with those with monoclonal gammopathy of undetermined significance (MGUS) and MGUS-free comparators, were recently published in Leukemia by Andersen et al.
Key data: Patients with SMM had significantly more infections (hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.07–1.73) and antibacterial prescriptions (HR, 1.24; 95% CI, 1.01–1.52) than the MGUS-free comparators, and more infections than patients with MGUS (HR, 1.37; 95% CI, 1.00–1.87).
Key learning: SMM confers an increased infection risk compared with both MGUS and individuals without MM precursors, representing an underrecognized need that warrants increased awareness among physicians and may inform preventive strategies and patient counseling.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
HCPs, which of the following best characterizes your perception of belantamab mafodotin in combination (BVd, BPd) for the treatment of relapsed/refractory multiple myeloma?